Treatment choices for newly diagnosed primary open angle and ocular hypertension patients

Abstract

Despite advances in our knowledge of the aetiology and pathophysiology of glaucoma, the sole proven, effective intervention for treating primary open angle glaucoma (POAG) and ocular hypertension (OHT) remains lowering of intraocular pressure (IOP) to prevent further progression and visual loss. The purpose of this review is to evaluate the treatment choices available to newly diagnosed POAG and OHT patients. We review the existing literature on current treatments available for newly diagnosed POAG and OHT patients and discuss their role in the treatment paradigm of POAG and OHT. We also consider different factors that may be important when offering a choice of treatment to newly diagnosed POAG and OHT patients. We describe new glaucoma treatments in development and future directions for treatment.

Cost-utility Analysis of Trabecular Micro-bypass Stents (TBS) in Patients With Mild-to-moderate Open-angle Glaucoma in Italy

“…An abnormality in the trabecular meshwork is the primary cause of reduced aqueous out ow, and therefore of increased IOP. Several therapeutic options are available to lower IOP, including medical therapy, laser trabeculoplasty (ALT/SLT), non-ltering micro-invasive glaucoma surgery (MIGS), anterior ltering surgeries, posterior ltering surgeries [6]. The choice of the optimal therapeutic intervention generally depends on several factors: the IOP level to be targeted, the entity of the anatomical eye damage induced by POAG, the disease progression rate, age and presence of comorbidities, level of ocular in ammation.…”

Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study

“…In our study of patients with POAG or OHT, once-daily dosages of netarsudil ophthalmic solution 0.02% for 7 mITT = modified intent-to-treat population; SD = standard deviation. a P < .05 b P < .01 c P < .001. the mean change in IOP in the treatment group, which decreased nearly 20% after 7 days of once-daily netarsudil treatment.…”

Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy

“…An abnormality in the trabecular meshwork is the primary cause of reduced aqueous outflow, and therefore of increased IOP. Several therapeutic options are available to lower IOP, including medical therapy, laser trabeculoplasty (ALT/SLT), non-filtering micro-invasive glaucoma surgery (MIGS), anterior filtering surgeries, posterior filtering surgeries [ 7 ]. The choice of the optimal therapeutic intervention generally depends on several factors: the IOP level to be targeted, severity of glaucomatous damage induced by POAG, the disease progression rate, age of the patient, presence of comorbidities and level of ocular inflammation.…”